Digestive Diseases and Sciences

, Volume 54, Issue 6, pp 1284–1291 | Cite as

Atypical Antipsychotic Quetiapine in the Management of Severe Refractory Functional Gastrointestinal Disorders

  • Madhusudan Grover
  • Spencer D. Dorn
  • Stephan R. Weinland
  • Christine B. Dalton
  • Bradley N. Gaynes
  • Douglas A. Drossman
Original Article


Management of severe refractory functional gastrointestinal disorders (FGIDs) is difficult. Quetiapine, an atypical antipsychotic, may benefit patients by mitigating associated anxiety and sleep disturbances, augmenting the effect of antidepressants, and providing an independent analgesic effect. Outpatient records from a university-based FGID clinic were reviewed, and 21 patients with refractory symptoms who received quetiapine were identified and interviewed. Outcomes included global relief of symptoms, treatment efficacy questionnaire, and change in gastrointestinal (GI) and psychological symptoms. Eleven of 21 patients continued therapy at the time of interview. Six of 11 demonstrated global relief of symptoms, and 9 were satisfied with treatment. The remaining 10 of 21 discontinued therapy because of somnolence and lack of GI benefits. Quetiapine in low doses appeared beneficial in more than half of the adults with severe FGIDs who stayed on treatment. This response in otherwise refractory patients suggests quetiapine might augment the effectiveness of antidepressants in severe FGIDs.


Irritable bowel syndrome Functional gastrointestinal disorders Treatment Psychotropic agents Antidepressants Quetiapine Atypical antipsychotics 



Supported by the Gastrointestinal Biopsycho-social Research Center at UNC, NIH R24Dk067674.


  1. 1.
    Creed F, Levy R, Bradley L, et al. Psychosocial aspects of functional gastrointestinal disorders. In: Drossman DA, Corazziari E, Delvaux M, et al., eds. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates Inc.; 2006:295–368.Google Scholar
  2. 2.
    Thiwan SM, Drossman DA. Treatment of functional GI disorders with psychotropic medicines: a review of evidence with a practical approach. Gastroenterol Hepatol. 2006;2:678–688.Google Scholar
  3. 3.
    Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243–1252. doi: 10.1056/NEJMoa052964.PubMedCrossRefGoogle Scholar
  4. 4.
    Lembo A, Ameen V, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol. 2005;3:717–725. doi: 10.1016/S1542-3565(05)00157-6.PubMedCrossRefGoogle Scholar
  5. 5.
    Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry. 2001;62(Supp 8):38–45. discussion 46–47.PubMedGoogle Scholar
  6. 6.
    Rotem AY, Sperber AD, Krugliak P, Freidman B, Tal A, Tarasiuk A. Polysomnographic and actigraphic evidence of sleep fragmentation in patients with irritable bowel syndrome. Sleep. 2003;26:747–752.PubMedGoogle Scholar
  7. 7.
    Fishbain DA, Cutler RB, Lewis J, Cole B, Rosomoff RS, Rosomoff HL. Do the second-generation “atypical neuroleptics” have analgesic properties? A structured evidence-based review. Pain Med. 2004;5(4):359–365. doi: 10.1111/j.1526-4637.2004.04054.x.PubMedCrossRefGoogle Scholar
  8. 8.
    Creswell JW. Research Design. Qualitative, Quantitative and Mixed Methods Approaches. 2nd ed. California: Sage Publications; 2003.Google Scholar
  9. 9.
    Drossman DA, Toner BB, Whitehead WE, et al. Cognitive behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125(1):19–31. doi: 10.1016/S0016-5085(03)00669-3.PubMedCrossRefGoogle Scholar
  10. 10.
    Drossman DA. The functional gastrointestinal disorders and the Rome III process. In: Drossman DA, Corazziari E, Delvaux M, et al., eds. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates Inc.; 2006:1–29.Google Scholar
  11. 11.
    Longstreth G, Thompson W, Chey W, Houghton L, et al. Functional bowel disorders. In: Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, et al., eds. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates Inc.; 2006:487–555.Google Scholar
  12. 12.
    Drossman DA, Talley NJ, Leserman J, Olden KW, Barreiro MA. Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med. 1995;123(10):782–794.PubMedGoogle Scholar
  13. 13.
    Ringel Y, Drossman DA, Leserman JL, et al. Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology. 2008;134(2):396–404. doi: 10.1053/j.gastro.2007.11.011.PubMedCrossRefGoogle Scholar
  14. 14.
    Whitehead WE, Palsson O, Jones KR. Systematic review of comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140–1156. doi: 10.1053/gast.2002.32392.PubMedCrossRefGoogle Scholar
  15. 15.
    Drossman DA, Whitehead WE, Toner BB, et al. What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol. 2000;95(4):974–980. doi: 10.1111/j.1572-0241.2000.01936.x.PubMedCrossRefGoogle Scholar
  16. 16.
    Hirschfeld RM, Weisler RH, Raines SR, Macfadden W, BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar 1 and bipolar 2 depression: a secondary analysis from a randomized, double blind, placebo-controlled study. J Clin Psychiatry. 2006;67:355–362.PubMedGoogle Scholar
  17. 17.
    Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004;45(1):17–28. doi: 10.1176/appi.psy.45.1.17.PubMedCrossRefGoogle Scholar
  18. 18.
    Tarazi FI, Zhang K, Baldessarini RJ. Long term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl). 2002;161(3):263–270. doi: 10.1007/s00213-002-1016-3.CrossRefGoogle Scholar
  19. 19.
    Creed F, Guthurie E, Ratcliffe J, et al. Does psychosocial treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder? Aust N Z J Psychiatry. 2005;39:807–815. doi: 10.1111/j.1440-1614.2005.01686.x.PubMedCrossRefGoogle Scholar
  20. 20.
    Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125:1651–1659. doi: 10.1053/j.gastro.2003.09.028.PubMedCrossRefGoogle Scholar
  21. 21.
    Drossman DA, Li Z, Leserman J, Toomey TC, Hu YJ. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology. 1996;110:999–1007. doi: 10.1053/gast.1996.v110.pm8613034.PubMedCrossRefGoogle Scholar
  22. 22.
    Schutters SI, van Megen HJ, Westenberg HG. Efficacy of quetiapine in generalized social anxiety disorder: results from an open label-study. J Clin Psychiatry. 2005;66:540–542.PubMedCrossRefGoogle Scholar
  23. 23.
    McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24:487–494. doi: 10.1002/da.20275.PubMedCrossRefGoogle Scholar
  24. 24.
    Goldstein JM. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc). 1999;35(3):193–210.Google Scholar
  25. 25.
    McConville B, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open label trial in adolescents with psychotic disorders. J Clin Psychiatry. 2000;61:252–260.PubMedGoogle Scholar
  26. 26.
    Fass R, Fullerton S, Tung S, Mayer EA. Sleep disturbances in clinic patients with functional bowel disorders. Am J Gastroenterol. 2000;95:1195–1200. doi: 10.1111/j.1572-0241.2000.02009.x.PubMedCrossRefGoogle Scholar
  27. 27.
    Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with post traumatic stress disorder: an open trial of adjuvant therapy. J Clin Psychopharmacol. 2003;23:15–20. doi: 10.1097/00004714-200302000-00003.PubMedCrossRefGoogle Scholar
  28. 28.
    Cohrs S, Rodenbeck A, Guan Z, et al. Sleep promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl). 2004;174:421–429.Google Scholar
  29. 29.
    Schreiber S, Getslev V, Backer MM. The atypical neuroleptics clozapine and olanzapine differ regarding their antipsychotic mechanisms and potency. Pharmacol Biochem Behav. 1999;64:75–80. doi: 10.1016/S0091-3057(99)00107-0.PubMedCrossRefGoogle Scholar
  30. 30.
    Shemo M, Shemo JPD, Anderson M. Beneficial effects of quetiapine treatment in patients with fibromyalgia. J Neuropsychiatry Clin Neurosci. 2003;15:282.Google Scholar
  31. 31.
    Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage. 2002;23:526–532. doi: 10.1016/S0885-3924(02)00391-3.PubMedCrossRefGoogle Scholar
  32. 32.
    Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:71–77. doi: 10.1016/j.pnpbp.2006.06.023.PubMedCrossRefGoogle Scholar
  33. 33.
    Pimentel M, Wallace D, Hallegua D, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63:450–452. doi: 10.1136/ard.2003.011502.PubMedCrossRefGoogle Scholar
  34. 34.
    Hellewell JSE, Hands DC, McKellar J. Seroquel: an effective atypical antipsychotic with no greater EP’S than placebo across the full dose range. Schizophr Res. 1998;29:154–155.Google Scholar
  35. 35.
    Brooke NS, Wiersgalla M, Salzman C. Atypical uses of atypical antipsychotics. Harv Rev Psychiatry. 2005;13:317–339. doi: 10.1080/10673220500433148.PubMedCrossRefGoogle Scholar
  36. 36.
    Drossman DA, Chang L. Psychosocial factors in the care of patients with GI disorders. In: Yamada T, ed. Textbook of Gastroenterology, Chapter 29. Philadelphia: Lippincott; 2003:636–654.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Madhusudan Grover
    • 1
    • 2
  • Spencer D. Dorn
    • 1
  • Stephan R. Weinland
    • 1
  • Christine B. Dalton
    • 1
  • Bradley N. Gaynes
    • 1
  • Douglas A. Drossman
    • 1
  1. 1.Center for Functional GI and Motility DisordersUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.Department of Internal MedicineMichigan State UniversityEast LansingUSA

Personalised recommendations